• Online GLP-1 prescriptions are often fast, easy — and low on clinical oversight, STAT News (7/6/26)

• After Makary’s Exit, FDA is giving CRL recipients another chance, Endpoints News (6/17/26)

• Genentech is soliciting research that can be used to blunt pharma reforms in Washington, STAT News (5/22/26)

• Pharma penalties for paying kickbacks to doctors failed to dent bottom lines, analysis finds, STAT News (3/24/26)

• Doctors Say Court Ruling Can’t Undo Kennedy’s Vaccine Damage, The New York Times (3/17/26)

• Continuous Glucose Monitoring on the Rise Among Medicare Advantage Members with Type 2 Diabetes, Morningstar (3/12/26)

• Lack of federal support means vaccine makers are less interested in R&D, Marketplace (2/17/26)

• ‍Here’s what parents need to know about the CDC’s updated childhood vaccine schedule, BCK (1/10/26)

• What parents should know about the new childhood immunization schedule, Yale School of Public Health (1/07/26)

‍ ‍

• With the Wegovy pill, Novo Nordisk undercuts Eli Lilly in direct-to-consumer market, STAT News (12/29/25)

• FDA Voucher program has become vehicle for political interference in drug review decisions, staffers say,STAT News (12/19/25)

• Safety label guidance: Commentators want clarity, transparency, and assurances, Regulatory Focus (11/24/25)

• Drugs are winning approval even when trials fail- but should they?, PharmaVoice (11/12/25)

• FDA moves to ease path for biosimilars as Trump seeks to cut drug costs,STAT News (10/29/25)

• Walz gets vaccinated, CDC recommends COVID-19 vaccine, Minnesota Reformer (10/13/25)

• Booming IV hydration spa industry needs more regulation, researchers say, Center for Science in the Public Interest (10/06/25)

• ‘It’s in this Gray Zone’: Study Calls for Tighter Oversight of IV Hydration Spas, MedPage Today (10/06/25)

• Hydration spas are largely unregulated, study finds, NBC News (10/06/25)

• The Fleming Initiative and Johns Hopkins combine forces against AMR, Imperial (9/29/25)

• Trump Tylenol Warning Kicks Off Label Change Drugmaker May Fight, Bloomberg Law (9/26/25)

• A look at the new COVID vaccine guidelines and what happened at ACIP, Yale School of Public Health (9/25/25)

• FDA takes on GLP-1 compounding boom with warnings about misleading marketing, STAT News (9/19/25)

• CDC’s vaccine advisers meet this week. Here’s how they could affect policy, NPR (9/18/25)

• Under Trump, FDA Seeks to Abandon Expert Reviews of New Drugs, Kaiser Family Foundation (9/12/25)

• FDA publishes drug rejection letters for ongoing drug applications, Endpoints News (9/04/25)

• Big Pharma Companies Paid 80% of Multiple Sclerosis Doctors $164 Million Over 5 Years, StudyFinds (8/28/25)

• Yale experts urge reforming- not gutting- PDUFA, Regulatory Focus (8/18/25)

• With New Authorities, FDA Continuing to Balance Access, Uncertainty in Accelerated Approval Process, Precision Medicine Online (8/11/25)

• RFK Jr.’s vow to overhaul vaccine injury program echoes grievances of anti-vaccine movement, ABC News (8/7/25)

• Drug, medical device industry paid physicians $13.2b in 2024, Healthcare Brew (7/11/25)

• F.D.A. Posts Collection of Letters Outlining Concerns About New Drugs, The New York Times (7/10/25)

• Confirming Hope: Validating Surrogate Endpoints To Support FDA Drug Approval Using An Inter-Agency Approach, Federation of American Scientists (7/08/25)

• Inside the Collapse of the F.D.A, The New York Times Magazine (7/08/25)

• When it comes to vaccines, how are pediatricians restoring trust?, NPR (7/07/25)

• FDA chief’s goals of ‘radical transparency’ threatened by agency cuts, STAT News (6/23/25)

• RFK Jr. Takes Aim at COVID Shots for Kids, Worrying Vaccine Experts, The Detroit News (5/08/25)

• The Science and Politics of Vaccines Collide, Yale Insights‌ (5/06/25)

• The End of Compounded GLP-1 Copies Leaves Many Patients in a ‘Lose-Lose’ Position, STAT News (4/29/25)

• How Marty Makary’s FDA is Embracing a More Skeptical View of Vaccines, STAT News (4/29/25)

• Key FDA Drug Data Goes Missing Amid DOGE Cuts, Axios (4/24/25)

• US FDA’s Makary Floats Vague ‘Plausible Mechanism’ Approval Pathway For Rare Diseases, Pink Sheet (4/22/25)

• CDC Officials Plan for the Agency’s Splintering, but Questions Remain, Associated Press (4/10/25)

• Kennedy’s Moves on Measles Don’t Quell Criticism, The Hill (4/09/25)

• “Guaranteed Pandemonium” as HHS Secretary Slashes Federal Health Workforce, JAMA Medical News (4/05/25)

• Connecticut Sues Trump Administration Over $150M in Public Health Cuts, Yale Daily News (4/04/25)

• 5 High-Level CDC Officials are Leaving in the Latest Turmoil for the Public Health Agency, Pittsburgh Post-Gazette (3/25/25)

• F.D.A. Nominee to Face Grilling Over Cutbacks and Policy Shifts, The New York Times (3/06/25)

• Weight Loss Drugs May Become Harder to Get. What Does that Mean for Patients? WBUR (2/28/25)

• ANALYSIS: RFK Jr.’s Health Revolution: Reform or Risk? Yale Daily News (2/28/25)

• On Measles Outbreak, the Trump Administration’s Messaging Strikes Some as Off-Key, STAT News (2/27/25)

• RFK Jr. Readies Review of Childhood Vaccine Schedule after Pledging Not to, Endpoints News (2/19/25)

• Doctors for America Discusses Lawsuit Against Federal Agencies, WGN 720 Radio (2/17/25)

• Study Finds Websites Aren’t Always Transparent About Compounded GLP-1 RAs, Medscape (2/13/25)

• US FDA Advisory Committee Freeze Raises Concerns of Delayed, more Controversial Approvals, Pink Sheet (2/10/25)

• RFK Jr. says he's not anti-vaccine in Senate confirmation hearing, KCBS Radio (1/29/25)

• ‘Incredibly irresponsible’: Hims Super Bowl ad downplays risks of compounded drugs,STAT News (1/28/25)

• What will happen to Medicare drug pricing negotiations under Trump?,MM+M (1/24/25)

• Advocates Slam US-Gilead Patent Settlement Over HIV PrEP Drugs,Bloomberg Law News (1/21/25)

• Misleading Statements Common in Online Ads for Compounded GLP-1s, tctMD (1/20/25)

• Online marketing for compounded GLP-1 drugs overstates benefits and underplays risks, STAT News (1/17/25)

• “E-sellers of compounded weight-loss drugs fail to reveal risks, research shows”, Reuters (1/17/25)

• Despite New FDA Guidance, Doctors Say Accelerated Approval Process Still Flawed, MedCentral (1/16/25)

• Federal watchdog raises some concerns about the FDA’s accelerated approval program, STAT News (1/14/25)

• How A Recent Supreme Court Decision May Have Already Hamstrung RFK Jr.'s Big Plans, Huffpost (11/30/24)

• RFK Jr will cut prescription drugs and increase weed and psychedelics access, The Guardian (11/25/24)

• Oncologists Left Needing Guidance After FDA-Approved Drugs Fail Confirmatory Trials, Oncology News Central (11/25/24)

• 'Very reductive': Experts warn against major HHS changes coming from Trump's nominee, RawStory (11/25/24)

• Intercept is denied full FDA approval for Ocaliva, but claims it will keep drug on market, Endpoint News (11/12/24)

• Trump Victory Gives RFK Jr. Free Rein to Shape Public Health, Bloomberg (11/06/24)

• Most Journal Articles Still Missing COI Statement on PubMed, MedPage Today (11/05/24)

• FDA Urged to Levy Fines for Delayed Confirmatory Trials in Oncology and Beyond, Oncology News Central (10/30/24)

• Yale experts weigh in on Harris’ Medicare expansion plan, Yale Daily News (10/28/24)

• 5 Accelerated Approvals Gone Wrong, BioSpace (10/14/24)

• Gilead Agrees to Allow Generic Version of Groundbreaking H.I.V. Shot in Poor Countries, New York Times (10/07/24)

• Most cardiovascular devices with serious safety recalls aren’t tested in patients, STAT News (9/26/24)

• [U.S. Senate Roundtable Conversation] Sanders to Announce New Information on the Production and Pricing of Blockbuster Diabetes and Weight-Loss Drugs Ozempic and Wegovy at Expert Discussion, U.S. Senate (9/17/24)

• Healthcare professionals back NICE decision to reject ‘cost ineffective’ Alzheimer’s treatment on cash-strapped NHS budget, research finds, Pharmiweb.com (9/09/24)

• Frequent Use of Surrogate Markers Could Create Uncertainty for Breakthrough-Designated Drugs, Pharmacy Times (8/29/24)

• Prices of common medications are being lowered—what you can expect, KCBS Radio (8/15/24)

• 'It's astronomical': AbbVie led the way in paying doctors to pitch its drugs last year, Medical Marketing and Media (7/13/24)

• Health Care Is About to Get Even More Litigious, Bloomberg (7/12/24)

• Oncology Community Worried About “Chevron Deference” Ruling - AACR Journals, AACR Journals (7/23/24)

• Environmentalists, Public Health Advocates Worry about Ability to Regulate Industry after, KQED (7/11/24)

• AbbVie dramatically outspent its pharma company rivals in 2023 to promote its drugs to doctors, STAT News (7/5/24)

• Researchers examine cancer drug guidelines and FDA approvals - Medical Xpress, Medical Xpress (7/02/24)

• How the Supreme Court has roiled U.S. health-care agencies, The Washington Post (7/02/24)

• Chevron Ruling Could Chill FDA's Public Health Efforts, Stem AI, LDT Regulation, Inside Health Policy (6/28/24)

• Yale CRRIT Researchers Examine Cancer Drug Guidelines and FDA Approvals, Yale School of Medicine (6/26/24)

• SCOTUS ruling on mifepristone could have lasting impact on FDA regulation: Experts, ABC7 New York (6/14/24)

• The Most Important Supreme Court Case You've Probably Never Heard Of - PJ Media, PJ Media (6/26/24)

• FDA Use of “Proxies” to Expedite Drug Approvals Not Supported by Evidence, Analysis Finds, Yale School of Medicine (5/28/24)

• Gene therapy for muscular dystrophy stirs hopes and controversy, Houston Public Media NPR (5/02/24)

• Prices of Expensive Diabetes Medicines and Weight-loss Drugs Are Drastically Higher than Production Costs, Yale School of Medicine (4/29/24)

• Diabetes Medication Can Be Manufactured at Lower Cost, New Study Says, Yale School of Medicine (4/24/24)

• About half of cancer drugs given accelerated approval don’t show improved survival or quality of life, STAT News (4/07/24)

• Graft much? Doctors received $12 billion from drug, device makers between 2013-2022, Science Blog (3/28/24)

• Sustainable Price Estimates for Diabetes Medicines Revealed, Mirage News (3/28/24)

• $5 Ozempic? New Study Sparks Calls for Novo Nordisk to cut prices, Becker’s Hospital Review (3/28/24)

• Georgia patients struggle to find drugs they need due to shortages, The Atlanta Journal-Constitution (3/06/24)

• Aduhelm’s Post-Marketing Studies: At Least One More Data Dump Likely Required by NIH, Pink Sheet Citeline Regulatory (2/21/24)

• Rx Shortages Prompt Search by Congress for a Lasting Solution, Specialty Pharmacy Continuum (12/01/23)

• Huge Spending — But Little Sharing of Research Results — on Cancer Drugs, UCLA Anderson Review (11/15/23)

• Americans Don’t Get to Have the Best New COVID Drug, The Atlantic (10/25/23)

• Phenylephrine, a Common Decongestant, Is Ineffective, Say FDA Advisors. It’s Not Alone, Yale School of Medicine News (10/05/2023)

• Health Subcommittee members at odds over drafted drug shortage legislation, Fierce Healthcare (9/15/23)

• House Democrats push back on Republicans’ drug shortage proposals during legislative hearing, Endpoints News (9/14/23)

• No 'Silver Bullet' for Generic Drug Shortage, House Members Told, Medpage Today (9/14/23)

• Yale Experts Discuss Impact of Medicare Price-negotiation Legislation, Yale Daily News (9/11/23)

• Yale Researchers Develop Nasal Spray mRNA Vaccine for COVID-19, Yale Daily News (9/08/23)

• (STUDY) 50% of paid staff at top patient advocacy groups have direct ties to Pharma industry, Sharyl Attkisson (8/27/23)

• Top Patient Advocacy Orgs Have Industry Ties in Leadership, Study Shows, Medpage Today (8/21/23)

• Vaccine Politics May be to Blame for GOP Excess Deaths, Washington Post (7/24/23)

• Newly approved Alzheimer's drug may not work as well on women, Axios (7/11/23)

• Novo Nordisk bought prescribers over 450,000 meals and snacks to promote drugs like Ozempic, STAT News (7/05/23)

• Is a gift ever just a gift, Substack.com (6/30/23)

• FDA’s Peter Marks overrode agency staff to approve Sarepta’s Duchenne gene therapy, Endpoints News (6/23/23)

• When Dying Patients Want Unproven Drugs, The New Yorker (6/19/23)

• The strain COVID vaccines might target next, Axios (6/15/23)

• How Much Delay In Alzheimer’s Disease Progression Is Clinically Meaningful, Pink Sheet (6/12/23)

• FDA removes neurologist with financial ties to Eisai and Biogen from Alzheimer’s advisory panel, STAT News (6/05/23)

• Alzheimer’s Groups Seek Broad Medicare Coverage for Pricey Drugs, Bloomberg Law (6/01/23)

• Promising new Alzheimer's drugs present patients with tough choices, Axios (5/15/23)

• Gene therapy for muscular dystrophy stirs hopes and controversy, NPR & Houston Public Media (5/02/23)

• Will New FDA Rules Help Dial Back Expedited Drugs?, Undark Magazine (4/12/23)

• Real-World Evidence For Accelerated Approval: NASEM Is A Tough Crowd, Pink Sheet (3/13/23)

• Clinical trials on new cancer drugs still fall far short of including key data on several demographic groups, Medical Xpress (2/23/23)

• Gold standard? 10% of newly approved drugs were based on studies that didn't achieve goals, USA Today (2/13/23)

• Lack of diversity in clinical trials is leaving women and patients of color behind and harming the future of medicine, The Conversation Podcast (2/09/23)

• Health experts want FDA safety review of fast-tracked Alzheimer's drug, Axios (2/06/23)

• Loophole enables FDA approval of unsafe medical devices, Yale study finds, Yale News (1/19/23)

• Reassuring Safety Inquiry But Botched Comms Leads To Mixed Headlines For Pfizer Bivalent Vax, Pink Sheet (1/16/23)

• Adding device identifiers to claims forms—a key step to advance medical device safety, BMJ (1/11/23)

• New Alzheimer's drug may have limited real-world impact, Axios (1/10/2023)

• Approval of a second controversial Alzheimer's drug is dividing medical experts, The Washington Post (1/09/23)